- Home
- ALXO vs IOBT Comparison
ALXO vs IOBT Comparison
Compare ALXO & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | IOBT |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 57.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALXO | IOBT |
|---|---|---|
| Price | $1.16 | $0.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.30 | ★ $3.50 |
| AVG Volume (30 Days) | 210.9K | ★ 688.2K |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.32 |
| 52 Week High | $2.27 | $2.79 |
Technical Indicators
Market Signals| Indicator | ALXO | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 36.34 |
| Support Level | $1.07 | $0.50 |
| Resistance Level | $1.56 | $0.55 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.43 | 2.75 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.